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journa l homepage : www.e lsev ier . com/ loca te / rmedLETTER TO THE EDITORResponse to letter by A. Garcı´a ArietaI thank Dr Arieta for his comment to the paper ‘‘Lung
function and asthma control with beclomethasone and
formoterol in a single inhaler’’ published on the January
issue of this Journal.1
He suggests that the superiority in some parameters of
asthma control achieved with beclomethasone (BDP)/for-
moterol (FF) extrafine HFA fixed combination over BDP CFC
and FF DPI given via separate inhalers is due to the extra-
fine nature of BDP in the fixed combination, rather than to
the co-deposition of BDP and FF in the lung allowed by the
co-administration of the active principles in a single
inhaler.
We agree that this explanation is in line both with the
pharmacokinetics data reported with the extrafine BDP/
FF combination2 and with previous evidence of superiority
of BDP extrafine versus BDP CFC in clinical parameters
different from lung function.3,4 This confirms the impor-
tance to have an extrafine formulation able to achieve
high lung deposition and homogeneous distribution
throughout the lung, including the small airways.
However, we believe that, based on the current knowl-
edge, the explanation of this interesting and novel finding
for an ICS/LABA combination might be more complex. The
synergistic effect of LABA and ICS is well documented at
various cellular levels, both in the central and in the
peripheral bronchial tree.5e8 When formulated as extra-
fine, ICS and LABA are expected to be efficiently and
homogeneously co-deposited in all the districts of the
lungs, as already shown in vitro with the extrafine HFA
BDP/FF combination under investigation.9Our hypothesis is
therefore that the extrafine formulation not only favours
the efficient lung deposition of BDP and its peripheral
distribution, as stated by Dr Arieta, but also allows the
efficient co-deposition of both the BDP and FF throughout
the lung, thus enabling the synergistic effect of the two
drugs in all the districts of the bronchial tree. Overall, this
would contribute to the clinical superiority observed in this
study over the separate, nonextrafine components, which
has never been reported for other nonextrafine ICS/LABA
fixed combinations.DOI of original article: 10.1016/j.rmed.2009.03.025.
0954-6111/$ - see front matter ª 2009 Elsevier Ltd. All rights reserved
doi:10.1016/j.rmed.2009.08.006The results of the study performed do not allow to
discriminate the separate contribution of the extrafine
formulation and the improved co-deposition due to the
single inhaler administration, therefore we hypothesised
that both features might concur in the beneficial effect on
asthma control observed with the extrafine BDP/FF
combination compared to nonextrafine BDP plus FF
administered as separate components.
Whether the property of ICS and LABA co-deposition and
its clinical benefit is attributable mainly to fixed combina-
tions rather than to free combinations, as suggested by
some authoritative investigators,10 should be definitively
demonstrated in a properly designed clinical trial.
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